Targets › RYR1
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Jan 2027.
Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. (UniProt, P21817)
Open in Phaseline: the race on RYR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| RyCarma Therapeutics | Surlorian (ARM210, S48168) Ryanodine receptor 1 (RYR1) activator | RYR1 | Phase 2 | Autosomal Dominant RYR1-Related Myopathy | Aug 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Dantrolene Ryanodine receptor antagonist | RYR1 | Phase 1 | Multiple Sclerosis | Jan 2027 |
Autosomal Dominant RYR1-Related Myopathy (1) Multiple Sclerosis (1)
small molecule (2)
RyCarma Therapeutics (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.